This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (INVIGORATE 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04209205
Recruitment Status : Completed
First Posted : December 24, 2019
Last Update Posted : April 21, 2023
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the Results Quality Control (QC) review process. Results information is submitted to by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Completed
Actual Primary Completion Date : May 17, 2022
Actual Study Completion Date : May 17, 2022
Certification/Extension First Submitted : October 4, 2022
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 May 8, 2023
June 5, 2023 Submission with QC Comments
2 June 30, 2023
July 25, 2023 Submission with QC Comments
3 August 23, 2023
September 11, 2023 Submission with QC Comments
4 November 3, 2023
November 7, 2023 Submission with QC Comments